NCT00517348

Study Evaluating IMA-026 in Healthy Subjects

Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IMA-026 Administered Subcutaneously or Intravenously to Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IMA-026 administered subcutaneously (SC) or intravenously (IV) in healthy adults.

Conditions

• Healthy

Interventions

Type	Name	Description
BIOLOGICAL	IMA-026	SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV

Timeline

• Start date: 2007-09-01
• Primary completion: 2008-07-01
• Completion: 2008-07-01
• First posted: 2007-08-16
• Last updated: 2009-06-25

Locations

1 site across 1 country: United States